IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Esperion Therapeutics, Inc. & Re...
February 08 2016 - 5:10AM
Business Wire
Lundin Law PC announces a class action lawsuit has been filed
against Esperion Therapeutics, Inc. (“Esperion” or the “Company”)
(NASDAQ: ESPR) concerning possible violations of federal securities
laws between August 18, 2015 and September 28, 2015. Investors who
purchased or otherwise acquired shares during the Class Period
should contact the Firm in advance of the March 14, 2016, lead
plaintiff motion deadline.
To participate in this class action lawsuit, please contact
Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via
e-mail at brian@lundinlawpc.com.
According to the complaint, the Company had no clear path to
approval for ETC-1002, the Company’s lead product candidate
designed to lower LDL-cholesterol levels. In addition, the FDA had
encouraged the Company to initiate a cardiovascular outcomes trial
(“CVOT”) and that completion of a CVOT could be necessary prior to
approval of ETC-1002.
No class has been certified in the above action. Until a class
is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class
member.
Lundin Law PC was created by Brian Lundin, a securities
litigator based in Los Angeles.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160208005424/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlaw.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024